Hope for Hard-to-Treat lung infection: new drug trial underway

NCT ID NCT02968212

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 24 times

Summary

This study tests a drug called clofazimine for people with a chronic lung infection caused by Mycobacterium avium complex (MAC). The goal is to see if adding clofazimine to standard treatment can clear the bacteria from sputum and improve walking ability and fatigue. About 102 adults with confirmed MAC lung disease are taking part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYCOBACTERIUM AVIUM COMPLEX are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Louisiana State University

    Baton Rouge, Louisiana, 70803, United States

  • National Jewish Health

    Denver, Colorado, 80206, United States

  • Oregon Health & Science University

    Portland, Oregon, 97239, United States

  • University of Chicago

    Chicago, Illinois, 60637, United States

  • University of South Florida

    Tampa, Florida, 33620, United States

  • University of Texas Health Science Center

    Tyler, Texas, 75708, United States

Conditions

Explore the condition pages connected to this study.